Cafepharma Today

March 27 2023 - Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
Novo's high-dose Rybelsus win tees up regulatory filings
BioNTech's COVID-19 vaccine revenue forecasts lower than expected
BrainStorm secures FDA adcomm for ALS therapy NurOwn
*please scroll down for all the latest news*

Current News

submit a press release

Click here to stay updated on CP happenings
Six-month Ozempic shortage mostly over after weight-loss craze drained supply
Seattle Times, WA
Monday, March 20, 2023 - 4:39pm
tags:
Novo Nordisk, drug shortages, Ozempic, diabetes, weight loss
California takes another step forward in its insulin production with $50M investment
Endpoints
Monday, March 20, 2023 - 4:37pm
tags:
California, insulin, diabetes
Olympus Smacked with One Doozy of a Warning Letter
Medical Devices and Diagnostics Industry
Monday, March 20, 2023 - 4:34pm
tags:
FDA, devices, Medtech, Olympus
Mer­ck, Vi­a­tris agree to set­tle patent feud sur­round­ing di­a­betes drugs
Endpoints
Monday, March 20, 2023 - 4:30pm
tags:
Merck, Viatris, patents, diabetes, Januvia, Janumet
Eli Lilly CEO racked up $21.4M in 2022 pay as stock price hit all-time high
Fierce Pharma
Monday, March 20, 2023 - 4:28pm
tags:
David Ricks, Pharma CEOs, executive compensation
Neurofilament as a surrogate endpoint goes on trial in tofersen adcomm
BioSpace
Monday, March 20, 2023 - 11:40am
tags:
ALS, Biogen, Ionis Pharmaceuticals, FDA, tofersen, clinical trials
In Another Blow To A Healthcare Delivery Industry In Cardiac Arrest, Amazon Just Closed A Blockbuster Deal With One Medical
Forbes
Monday, March 20, 2023 - 11:33am
tags:
Amazon, Healthcare, One Medical, telehealth
Incyte reports data from Phase IIb vitiligo therapy trial
Clinical Trials Arena
Monday, March 20, 2023 - 11:27am
tags:
Incyte, povorcitinib, vitiligo, clinical trials
AbbVie’s Skyrizi hits the spot in refractory psoriasis
Pharmaphorum
Monday, March 20, 2023 - 11:21am
tags:
AbbVie, Skyrizi, psoriasis
AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?
Fierce Pharma
Monday, March 20, 2023 - 10:06am
tags:
Sanofi, Regeneron, Dupixent, COPD
FDA's Robert Califf calls on insurers to help providers participate in critical clinical drug trials
Fierce Healthcare
Monday, March 20, 2023 - 10:01am
tags:
Robert Califf, FDA, insurers, clinical trials
Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
Fierce Biotech
Monday, March 20, 2023 - 9:56am
tags:
Zymeworks, Daiichi Sankyo, immuno-oncology, biobucks
Takeda Oncology Invests in Talent, Pipeline Growth Despite Turbulent Market
BioSpace
Monday, March 20, 2023 - 9:55am
tags:
Takeda Oncology, innovation, Hutchmed
Karuna’s schizophrenia drug succeeds in a second late-stage trial
BioPharma Dive
Monday, March 20, 2023 - 9:53am
tags:
Karuna, clinical trials, schizophrenia, KarXT
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
BioSpace
Monday, March 20, 2023 - 9:51am
tags:
Sangamo Therapeutics, Novartis, Biogen, neurology, gene regulation therapies
J&J finalizes $25M settlement, laying Remicade antitrust allegations to rest
Endpoints
Monday, March 20, 2023 - 9:50am
tags:
JNJ, legal, Remicade, antitrust, biosimilars
Eli Lilly signs CSO Daniel Skovronsky to $5M non-compete clause
Medical Marketing and Media
Monday, March 20, 2023 - 9:47am
tags:
Eli Lilly, executives, Daniel Skovronsky, CSO
Takeda, chasing Bristol Myers, unveils awaited TYK2 drug data
BioPharma Dive
Sunday, March 19, 2023 - 1:46pm
tags:
Takeda, Bristol Myers Squibb, clinical trials, TAK-279, plaque psoriasis
Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile
Fierce Biotech
Sunday, March 19, 2023 - 1:43pm
tags:
Gossamer Bio, clinical trials, GB5121, lymphoma
Pear Therapeutics Looks For A Buyer As It Struggles To Get Paid For Prescription Apps
Forbes
Sunday, March 19, 2023 - 1:40pm
tags:
Pear Therapeutics, digital therapeutics, FDA, Medtech, insomnia, M&A

Pages

Latest CP Wire Articles

PharmaBlock Opens New R&D Facility in Pennsylvania ——Expanding Capacity to Deliver GMP Projects
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Klick Health launches new healthcare venture studio
Medtech earnings reports: insights from major players' Q4 results
Key compliance issues for medtech firms transitioning to data-enabled solutions
Following FDA COVID vaccine advisory panel vote, Novavax is prepared to provide a revised vaccine
First-of-its-kind Whole Lung Simulator is Helping Michigan Researchers Predict New Treatments and Vaccines for TB – A Reemerging Global Health Threat
Novartis signs agreement with UN-backed Medicines Patent Pool to license generics of its CML drug
Korean firm LG Chem buying AVEO Oncology for $566M

Latest Pharmagather Articles

Behind the GoodRx-Express Scripts Partnership: How PBMs Profit from Discount Cards in Pharmacy Benefits (rerun)
Drug Channels
Winning the Race for Patient Access: Identifying Copay Accumulator Impact
Drug Channels
Gene Drives Are Coming
In the Pipeline
Organizing Our Thoughts About Cells - Finally
In the Pipeline
Drug Channels News Roundup, March 2023: My $0.02 on Insulin Price Cuts, AbbVie vs. AFPs, Optum Expands, ASAP340B, and Hooray for Pharmacists
Drug Channels
The Right Assay With the Right Cells
In the Pipeline
Informa Connect’s Annual Life Sciences Commercial Contracts & Chargebacks Congress
Drug Channels
Peptide-Encoded Screening Libraries
In the Pipeline
It's Not All Bad News: Data Shows There's a Collaborative Future for 340B
Drug Channels

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.

Do Not Allow Advertisers to Use My Personal information